



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 04-423-F (400.227US))

ITW
F

In the Application of:

McSwiggen et al.

Serial No.: 10/576,752

Filing Date: November 14, 2006

For: RNA Interference Mediated Inhibition
of GPRA and AAA1 Gene Expression
Using Short Interfering Nucleic Acid
(siNA)

) Examiner: Chong, Kimberly

) Group Art Unit: 1635

) Confirmation No.: 1907

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached papers for the above identified new patent application:
 - Information Disclosure Statement;
 - Information Disclosure Statement (IDS) PTO-1449 Form;
 - Copies of IDS Citations for S/N 10/576,752 (Total 2 foreign patents and 4 other documents); and
 - Return Receipt Postcard.
2. With respect to additional fees, enclosed is a check in the amount of \$180.00.
3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450 on August 6, 2007.

By :


Emily Miao, Ph.D.
Reg. No. 35,285



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 04-423-F (400.227US))

In the Application of:)
McSwiggen et al.)
Serial No.: 10/576,752) Examiner: Chong, Kimberly
Filing Date: November 14, 2006) Group Art Unit: 1635
For: RNA Interference Mediated Inhibition) Confirmation No.: 1907
of GPRA and AAA1 Gene Expression)
Using Short Interfering Nucleic Acid)
(siNA))

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Sections 1.56 and 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. A partial recitation of the priority claim is as follows. This application is a continuation-in-part of US Serial No. 10/826,966, filed April 16, 2004. This application is also a continuation-in-part of US Serial No. 10/780,447, filed February 13, 2004. This application is also a continuation-in-part of US Serial No. 10/727,780, filed December 3, 2003. All of the applications recited herein are relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 CFR §1.98(d), all references marked with an "*" have been previously cited and submitted to the Patent and Trademark Office with the prior applications. Additional references, if any, are numbered and submitted herein. All references cited are also listed in the PTO-1449 form enclosed herewith.


08/08/2007 RFEKADU1 00000002 10576752
180.00 OP
01 FC:1806

Portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants enclose the fee of \$180.00 pursuant to 37 C.F.R. 1.17(p) for this filing. The Commissioner is hereby authorized to charge or credit Deposit Account Number 13-2490 for any under- or over-payment of fees associated with the papers transmitted herewith, or to credit any overpayment of same.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP



Emily Miao, Ph.D.
Reg. No. 35,285

Date: August 6, 2007 By:

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, IL 60606
Telephone: 312-913-0001
Facsimile: 312-913-0002

FORM PTO-1449
(Rev. 2-32)

**U.S. Department of Commerce
Patent and Trademark Office**

Atty. Docket No.


Serial No.

04-423-F
(400/227US)

10/576,752

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



Applicant:
McSwiggen et al.

Filing Date: November 14, 2006 **Group:** 1635

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial	Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
*	US-2002/0086356	03/30/01	Tuschl et al.			07/04/02
*	US-2002/0151693	02/08/01	Breaker et al.			10/17/02
*	US-2003/0059944	09/13/02	Lois-Caballe et al.			03/27/03
*	US-2003/0064945	07/25/01	Akhtar et al.			04/03/03
*	US-2003/0143732	08/30/02	Fosnaugh et al.			07/31/03
*	US-2003/0190635	07/25/02	McSwiggen et al.			10/09/03
*	US-2003/0206887	09/16/02	Morrissey et al.			11/06/03
*	US-2004/0019001	07/26/02	McSwiggen et al.			01/29/04
*	US-2004/0161844	11/04/03	Baker et al.			08/19/04
*	US-2005/0020521	09/25/05	Rana, Tariq M.			01/27/05
*	US-2005/0182005	05/13/04	Tuschl et al.			02/18/05
*	US-2005/0227256	11/26/04	Hutvagner et al.			10/13/05

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
*	5,587,471	12/24/96	Cook et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

**U.S. Department of Commerce
Patent and Trademark Office**

Atty. Docket No.
04-423-F
(400/227US)

Serial No.
10/576,752

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:
McSwiggen et al.

Filing Date: November 14, 2006	Group: 1635
--	-----------------------

*	5,801,154	09/01/98	Baracchini et al.			
*	5,814,620	09/29/98	Robinson et al.			
*	5,898,031	04/27/99	Crooke, Stanley T.			
*	5,998,148	12/07/99	Bennett et al.			
*	5,998,203	12/07/99	Matulic-Adamic et al.			
*	5,998,206	12/07/99	Cowsert			
*	6,060,456	05/09/00	Arnold et al.			
*	6,107,094	08/22/00	Crook, Stanley T.			
*	6,214,805	04/10/01	Torrence et al.			
*	6,346,398	02/12/02	Pavco et al.			
*	6,506,559	01/14/03	Fire et al.			
*	6,573,099	06/03/03	Graham et al.			
*	6,824,972	11/30/04	Kenrick et al.			
*	7,022,828	04/04/06	McSwiggen et al.			
*	7,078,196	07/18/06	Tuschl et al.			

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 04-423-F (400/227US)	Serial No. 10/576,752
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant: McSwiggen et al.	
				Filing Date: November 14, 2006	Group: 1635

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
*	2001240375 (Old Application No. 40375/01)	03/16/01	AU (Graham et al.)				
*	2,359,180	08/03/00	CA (Kreutzer et al.)				
*	1325955	01/04/02	EP (Klippe-Gese et al.)				
*	1389637	08/05/02	EP (Klippe et al.)				
*	1144623 B1	01/29/02	EP (Kreutzer et al.)				
*	08208687	08/13/96	JP (Hotoda et al.) ABSTRACT ONLY				
*	90/14090	11/29/90	WO (Gillespie et al.)				
1.	94/01550	01/20/94	WO (Agrawal et al.)				
*	95/04142	02/09/95	WO (Robinson)				
*	99/04819	02/04/99	WO (Klimuk)				
*	99/07409	02/18/99	WO (Deschamps de Paillette et al.)				
*	99/14226	03/25/99	WO (Wengel et al.)				
*	99/32619	07/01/99	WO (Fire et al.)				

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

**U.S. Department of Commerce
Patent and Trademark Office**

Atty. Docket No.

04-423-F
(400/227US)

Serial No.

10/576,752

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:
McSwiggen et al.

Filing Date:

November 14, 2006

Group:

1635

*	99/49029	09/30/99	WO (Graham et al.)				
*	99/53050	10/21/99	WO (Waterhouse et al.)				
*	99/55857	11/04/99	WO (Beigelman et al.)				
*	99/61631	12/02/99	WO (Heifetz et al.)				
*	00/01846	01/13/00	WO (Plaetinck et al.)				
*	00/21560	04/20/00	WO (Alitalo et al.)				
*	00/44895	08/03/00	WO (Kreutzer et al.)				
*	00/44914	08/03/00	WO (Li et al.)				
*	00/49035	08/24/00	WO (Sheen)				
*	00/63364	10/26/00	WO (Pachuk et al.)				
*	01/04313	01/18/01	WO (Satischchandran et al.)				
*	01/29058	04/26/01	WO (Mello et al.)				
*	01/36646	05/25/01	WO (Zernicka-Goetz et al.)				
*	01/38551	05/31/01	WO (Grossniklaus)				
*	01/42443	06/14/01	WO (Churikov et al.)				
*	01/49844	07/12/01	WO (Driscoll et al.)				
*	01/53475	07/26/01	WO (Cogoni et al.)				
*	01/68836	09/20/01	WO (Beach et al.)				
*	01/70944	09/27/01	WO (Honer et al.)				
*	01/70949	09/27/01	WO (Graham et al.)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-423-F (400/227US)	Serial No. 10/576,752
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
Applicant: McSwiggen et al.			
Filing Date: November 14, 2006		Group: 1635	

*	01/72774	10/04/01	WO (Deak et al.)				
*	01/75164	10/11/01	WO (Tuschl et al.)				
*	01/92513	12/06/01	WO (Arndt et al.)				
*	01/96584	12/20/01	WO (Mushegian et al.)				
*	01/97850	12/27/01	WO (Siemeister et al.)				
*	02/07747	01/31/02	WO (King)				
*	02/10378	02/07/02	WO (Cowser et al.)				
*	02/22636	03/21/02	WO (Bennett et al.)				
*	02/38805	05/16/02	WO (Echeverri et al.)				
*	02/44321	06/06/02	WO (Tuschl et al.)				
*	02/055692	01/09/02	WO (Kreutzer et al.)				
*	02/055693	01/09/02	WO (Kreutzer et al.)				
*	02/096927	12/05/02	WO (Escobedo et al.)				
*	03/044188	11/21/02	WO (Tei et al.)				
*	03/064625	08/07/03	WO (Woolf et al.)				
*	03/064626	08/07/03	WO (Woolf et al.)				
*	03/068797	08/21/03	WO (Rossi et al.)				
*	03/070887	08/28/03	WO (McSwiggen et al.)				
*	03/070896	08/28/03	WO (McSwiggen et al.)				
*	03/070910	08/28/03	WO (McSwiggen et al.)				

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

04-423-F
(400/227US)

Serial No.

10/576,752

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:
McSwiggen et al.

Filing Date:

November 14, 2006

Group:

1635

*	03/074654 (PCT/US03/05028)	09/12/03	WO (McSwiggen et al.)				
*	03/080638	10/02/03	WO (LaCasse et al.)				
*	04/029212	04/08/04	WO (Rana, Tariq M.)				
*	04/043977	05/27/04	WO (Prakush et al.)				
*	04/048566	11/21/03	WO (Saigo et al.)				
2.	04/056866	07/08/04	WO (Laitinen et al.)				
*	04/072261	08/26/04	WO (Li et al.)				
*	04/090105	10/21/04	WO (Leake et al.)				
*	05/049821	11/18/04	Naito et al.				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

*	Adah et al., "Chemistry and Biochemistry of 2',5'-Oligoadenylate-Based Antisense Strategy," <i>Current Medicinal Chemistry</i> , 8, 1189-1212 (2001)
*	Alexeev et al., "Localized in vivo genotypic and phentypic correction of the albino mutation in skin by RNA-DNA oligonucleotide," <i>Nature Biotechnology</i> , 18:43-47 (2000)
*	Bahramian et al., "Transcriptional and Posttranscriptional Silencing of Rodent α 1(I) Collagen by a Homologous Transcriptionally Self-Silenced Transgene," <i>Molecular and Cellular Biology</i> , 274-283 (1999)
*	Bass, "Double-Stranded RNA as a Template for Gene Silencing," <i>Cell</i> , 101, 235-238 (2000)
*	Bass, "The short answer," <i>Nature</i> 411:428-429 (2001)
*	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglyceryl derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-423-F (400/227US)	Serial No. 10/576,752
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
Applicant: McSwiggen et al.			
Filing Date: November 14, 2006	Group: 1635		

*	Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <i>The Journal of Biological Chemistry</i> 270:25702-25708 (1995)
*	Bellon et al., "4-Thio-oligo-β-D-ribonucleotides: synthesis of β-4'-thio-oligouridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase," <i>Nucleic Acids Research</i> , 21(7):1587-1593 (1993)
*	Bernstein et al., "Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference," <i>Nature</i> 409:363-366 (2001)
*	Bernstein et al., "The rest is silence," <i>RNA</i> , 7:1509-1521 (2001)
*	Bitko et al., "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses," <i>BMC Microbiology</i> , 1:34 (11 pgs) (2001)
*	Braasch et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression," <i>Biochemistry</i> , 31:14, 4503-4510 (2002)
*	Braasch et al., "RNA Interference in Mammalian Cells by Chemically-Modified RNA," <i>Biochemistry</i> , 42, 7967-7975 (2003)
3.	Caplen, Natasha J., "RNAi as a gene therapy approach," <i>Expert Opin. Biol. Ther.</i> , 3(4):575-586 (2003)
*	Chiu et al., "siRNA function in RNAi: A chemical modification analysis," <i>RNA</i> , 9:1034-1048 (2003)
*	Claverie, Jean-Michel, "Fewer Genes, More Noncoding RNA," <i>Science</i> , 309, 1529-1530 (2005)
*	Clemens et al., "The Double-Stranded RNA-Dependent Protein Kinase PKR: Structure and Function," <i>Journal of Interferon and Cytokine Research</i> , 17:503-524 (1997)
*	Czech, Michael P., "MicroRNAs as Therapeutic Targets," <i>The New England Journal of Medicine</i> , 354, 1194-1195 (2006)
*	Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213 (2002)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

04-423-F
(400/227US)

Serial No.

10/576,752

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:
McSwiggen et al.

Filing Date:

November 14, 2006

Group:

1635

*	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> 411:494-498 (2001)
*	Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in <i>Drosophila Melanogaster</i> Embryo Lysate," <i>The EMBO Journal</i> 20:6877-6888 (2001)
*	Elbashir et al., "RNA Interference is Mediated by 21- and 22-Nucleotide RNAs," <i>Genes and Development</i> 15:188-200 (2001)
*	Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in <i>Caenorhabditis Elegans</i> ," <i>Nature</i> 391:806-811(1998)
*	Fire, "RNA-triggered Gene Silencing," <i>TIG</i> 15:358-363(1999)
*	Futami et al., "Induction of Apoptosis in HeLa Cells with siRNA Expression Vector Targeted Against bcl-2," <i>Nucleic Acids Research Supplement</i> 2:251-252 (2002)
*	Hamasaki et al., "Short interfering RNA-directed inhibition of hepatitis B virus replication," <i>FEBS Letters</i> , 543:51-54 (2003)
*	Hamilton, et al., "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants," <i>Science</i> , 286, 950-952 (1999))
*	Hammond et al., "An RNA-Directed Nuclease Mediates Post-Transcriptional Gene Silencing in <i>Drosophila</i> Cells," <i>Nature</i> 404:293-296 (2000)
*	Hammond et al., "Post-Transcriptional Gene Silencing by Double-Stranded RNA," <i>Nature</i> , 2:110-119 (2001)
*	Harborth et al., "Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing," <i>Antisense and Nucleic Acid Drug Development</i> , 13:83-105 (2003)
*	Hasan et al., "VEGF antagonists," <i>Oncologic, Metabolic & Endocrine</i> , 703-718 (2001)
*	Holen et al., "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor," <i>Nucleic Acids Research</i> , 30:8, 1757-1766 (2002)
*	Hornung et al., "Sequence-specific potent induction of IFN- α by short interfering RNA in plasmacytoid dendritic cells through TLR7," <i>Nature Medicine</i> , 11, 263-270 (2005)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-423-F (400/227US)	Serial No. 10/576,752
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: November 14, 2006	Group: 1635

*	Hutvagner et al., "A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the let-7 Small Temporal RNA," <i>Science</i> 293:834-838 (2001)
*	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> , 18:307-319 (2000)
*	Judge et al., "Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA," <i>Nature Biotechnology</i> , 23(4):457-462 (2005)
*	Kawasaki et al., "Uniformly Modified 2'-Modified 2'-Deoxy-2'-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets," <i>J. Med. Chem.</i> , 36, 831-841 (1993)
*	Kuwabara et al., "A <i>C. elegans</i> patched gene, ptc-1, functions in germ-line cytokinesis," <i>Genes and Development</i> , 14(15):1933-1944 (2000)
4.	Laitinen et al., "Characterization of a Common Susceptibility Locus for Asthma-Related Traits," <i>Science</i> , 304:300-304 (2004)
*	Leirdal et al., "Gene silencing in mammalian cells by preformed small RNA duplexes," <i>Biochemical and Biophysical Research Communications</i> , 295, 744-748 (2002)
*	Lin et al., "A Novel mRNA-cRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001)
*	Lin et al., "Policing rogue genes," <i>Nature</i> , 402, 128-129 (1999)
*	Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <i>Cell</i> 110:563-574 (2002)
*	Mattick, John S., "The Functional Genomics of Noncoding RNA", <i>Science</i> , 309, 1527-1528 (2005)
*	McCaffrey et al., "RNA interference in adult mice," <i>Nature</i> , 148, 38-39 (2002)
*	Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression," <i>J. Biol. Chem.</i> 268:14514-14522 (1993)
*	Morvan et al., "Comparative Evaluation of Seven Oligonucleotide Analogues as Potential Antisense Agents," <i>J. Med. Chem.</i> , 36, 280-287 (1993)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-423-F (400/227US)	Serial No. 10/576,752
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: November 14, 2006	Group: 1635

*	Olie et al., "Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide," <i>Biochimica et Biophysica Acta</i> , 1576, 101-109 (2002)
*	Opalinska et al., "Nucleic-Acid Therapeutics: Basic Principles and Recent Applications," <i>Nature Reviews Drug Discovery</i> , (1):503-514 (2002)
5.	Parrish, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," <i>Molecular Cell</i> 6:1077-1087 (2000)
6.	Sandrasagra et al., "RASONs: a novel antisense oligonucleotide therapeutic approach for asthma," <i>Exper Opin. Biol. Ther.</i> , 1(6):979-983 (2001)
*	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <i>Nucleic Acids Research</i> 24:573-581 (1996)
*	Sethupathy et al., "TarBase: A comprehensive database of experimentally supported animal microRNA targets," <i>RNA</i> , 12:192-197 (2006)
*	Sharp et al., "RNAi and double-strand RNA," <i>Genes & Development</i> , 13:139-141 (1999)
*	Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found," <i>Molecular Biology</i> , Vol. 286, No. 5441, p. 886 (1999) [sometimes mistakenly referred to as being published in <i>Science</i>]
*	Thomson et al., "Activity of hammerhead ribozymes containing non-nucleotidic linkers," <i>Nucleic Acids Research</i> 21:5600-5603 (1993) (MAY BE REFERRED TO AS THOMPSON)
*	Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for Analysis of Gene Function and Gene Therapy," <i>Molecular Interventions</i> , 295, 3, 158-167 (2002)
*	Tuschl et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," <i>Genes & Development</i> 13: 3191-3197 (1999)
*	Tuschl, "RNA Interference and Small Interfering RNAs," <i>Chembiochem</i> 2:239-245 (2001)
*	Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," <i>Journal of Biological Chemistry</i> , 278, 7108-7118 (2003)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

**U.S. Department of Commerce
Patent and Trademark Office**

Atty. Docket No.

04-423-F
(400/227US)

Serial No.

10/576,752

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:
McSwiggen et al.

Filing Date:

November 14, 2006

Group:

1635

*	Waterhouse et al., "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA," Proc. Natl. Acad. Sci. USA, 95, 13959-13964 (1998)
*	Wianny and Zernicka-Goetz et al., "Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development," <u>Nature Cell Biology</u> 2:70-75 (2000)
*	Zamore et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," <u>Cell</u> 101:25-33 (2000)
*	Zhang et al., "Single Processing Center Models for Human Dicer and Bacterial RNase III," <u>Cell</u> , 118:57-68 (2004)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.